News
OCSAW
19.08
0.00%
0.00
Oculis Holding (OCS) Gets a Buy from LifeSci Capital
TipRanks · 8h ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 1d ago
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
TipRanks · 2d ago
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
Barchart · 2d ago
Oculis Holding Price Target Raised to $46.00/Share From $40.00 by Needham
Dow Jones · 4d ago
Oculis Holding Is Maintained at Buy by Needham
Dow Jones · 4d ago
Needham Maintains Buy on Oculis Holding, Raises Price Target to $46
Benzinga · 4d ago
Oculis price target raised to $47 from $44 at H.C. Wainwright
TipRanks · 4d ago
Oculis Holding Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 4d ago
Oculis Holding Price Target Raised to $47.00/Share From $44.00 by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $47
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Oculis Holding (OCS) and Aligos Therapeutics (ALGS)
TipRanks · 4d ago
Oculis price target raised to $44 from $43 at BofA
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Apogee Therapeutics (APGE)
TipRanks · 4d ago
Oculis Plans NDA Submission For OCS-01 In Diabetic Macular Edema In Q4
NASDAQ · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ligand Pharma (LGND), Pliant Therapeutics (PLRX) and Oculis Holding (OCS)
TipRanks · 4d ago
Oculis Holding (OCS) Gets a Buy from Chardan Capital
TipRanks · 4d ago
Oculis reports Q1 EPS (49c), consensus (41c)
TipRanks · 5d ago
Oculis Holding GAAP EPS of CHF -0.49
Seeking Alpha · 5d ago
Oculis Holding Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $266.845K Miss $320.000K Estimate
Benzinga · 5d ago
More
Webull provides a variety of real-time OCSAW stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCSAW
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.